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First-derivative ultraviolet spectrophotometric and high performance
liquid chromatographic determination of ketoconazole in pharmaceutical
emulsions
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First-derivative ultraviolet spectrophotometric (Method I) and
reversed phase high performance liquid chromatographic (Method
II) methods were developed. The validated methods were applied
for quantitative determination of ketoconazole in commercial and
simulated emulsion formulations. Quantitative first-derivative UV
spectrophotometric determinations were made using the zero-crossing
method at 257 nm, with methanol as background solvent. Liquid
chromatographic analysis was carried out on a LiChrospher® 100
RP-18 (5μm) column. A mixture of triethylamine in methanol
(1:500 v/v) and 0.5% ammonium acetate solution (75:25 v/v) was
used as mobile phase at a flow rate of 1.0 mL/min with UV detection
at 225 nm. The retention time of ketoconazole and terconazole were
3.9 min and 5.9 min, respectively, the later being used as internal
standard. Analytical curves were linear within a concentration range
from 5.0 to 30.0 μg/mL for Method I and 20.0 to 80.0 μg/mL for
Method II, with correlation coefficients of 0.9997 and 0.9981,
respectively. The relative standard deviation (RSD) was 0.56% and
0.41% for simulated and commercial emulsion formulations,
respectively, using Method I. The corresponding values were 2.13%
and 1.25%, respectively, using Method II. The percentage recoveries
were above 100% for both methods. The excipients did not interfere
in the analysis. The results showed that either method can be used
for rapid ketoconazole determination in pharmaceutical emulsions
with precision, accuracy and specificity.
INTRODUCTION
Ketoconazole is an imidazole derivative with a wide
antifungal spectrum and possesses some antibacterial
activity (El-Shabouri et al., 1998; Hardman, Limbird,
Gilman, 2001; Korolkovas, 1988).
Ketoconazole, [(±)-cis-1-acetyl-4-(4-{[2-(2,4-
dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-
4-yl] methoxy} phenyl) piperazine] (Figure 1), is widely used
in the treatment of dermal and systemic mycoses.
Ketoconazole presents advantage over other imidazole
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administration (Abounassif, El-Shazly, 1989; Hardman,
Limbird, Gilman, 2001; Korolkovas, 1988).
Ketoconazole commercially available in several
dosage forms for oral and topical administration. Through
the oral route, it could provoke hepatotoxicity and interfe-
re with the metabolism of testosterone (Abounassif, El-
Shazly, 1989; El-Shanawany et al., 1997; Katsambas et al.,
1989; Korolkovas, 1988; Low, Wangboonskul, 1999;
Roychowdhury, Das, 1996). Topical ketoconazole
formulations have been found to be effective in controlling
seborrhoeic dermatitis without producing significant
adverse reactions (Katsambas et al., 1989; Roychowdhury,
Das, 1996). It is active against pityrosporum yeasts both “in
vitro” and “in vivo” (El-Shabouri et al., 1998).
Several analytical methods have been developed for
quantitative determination of ketoconazole, among them
visible spectrophotometry (Abdel-Gawad, 1997),
ultraviolet (UV) spectrophotometry (El-Shabouri et al.,
1998; Kedor-Hackmann, Nery, Santoro, 1994),
spectrofluorimetry (El-Shanawany et al., 1997), thin-layer
chromatography (Roychowdhury, Das, 1996), supercritical
fluid chromatography with UV detection (Ashraf-
Khorassani, Levy, 1995), capillary electrophoresis with
diode array detection (Arranz et al., 2000), high
performance liquid chromatography (HPLC) using
different detection modes such as UV (Al-Meshal, 1989;
Abdel-Moety et al., 2002; Heyden et al., 2002), diode array
(Koves, 1995) and electrochemical detection (Hoffman et
al., 1988), and stripping voltametric and polarographic
techniques (Arranz et al., 2003). However, no reference was
found using first-derivative UV spectrophotometric
determination of ketoconazole in emulsions.
The official compendia (British Pharmacopoeia,
2000; United States Pharmacopeia, 2005) describe
analytical methods for quantitative determination of
ketoconazole in tablets and oral suspension, however
no validated method was found for its quantitative
determination in pharmaceutical emulsions.
The objective of this work was to develop sensitive and
efficient analytical methods for quantitative determination of
ketoconazole in pharmaceutical emulsions. Two methods were
developed and validated for this purpose, using first-derivative
UV spectrophotometry (Method I) and HPLC (Method II).
MATERIAL AND METHODS
Instrumentation
A Beckman model DU-70 spectrophotometer
with quartz cells of 1 cm path length connected to an
Epson-Fx 850 printer was used. The HPLC separations
were made on a system comprised of a solvent delivery
pump (model 480-C), a variable UV detector set at 225
nm connected to an integrator (model CG-200) (Instru-
mentos Científicos CG Ltda, São Paulo, Brasil). The
system was equipped with a manual Rheodyne® 7125
injection valve, fitted with a 20 µL loop. The analytical
column was a LiChrospher® 100 RP-18 (5 µm) (125 x
4 mm) in a LiChroCART® (Merck®,  Darmstadt,
Germany). A Digimed® pH meter (model T-901) and a
Thornton® sonicator (model T-14) were also used.
Reference substances, reagents and solutions
Ketoconazole (99.5%) and terconazole (99.2%)
active pharmaceutical ingredients were donated by
pharmaceutical firms and were used as reference
standards without further purification. All reagents and
solvents were of analytical grade. The solvents used in
the mobile phase were HPLC grade. Distilled water was
purified using a Milli-Q® Plus System (Millipore®,
Milford, MA, USA).
Two sample matrixes were selected for analysis.
The simulated emulsion sample (sample 1) was prepared
in our laboratory according to the formula given in Table
I. The commercial sample was obtained from a local
pharmaceutical firm (sample 2).
METHODS
First-derivative UV Spectrophotometry (Method I)
Methanol solutions in a concentration range from
5.0 to 30.0 µg/mL were prepared to obtain the analytical
curve. Absorption intensities were measured at 257 nm
FIGURE 1 – Chemical structures of ketoconazole (A) and
terconazole (B).
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using methanol as blank, scanning velocity was 300 nm/
min and quartz cells of 1 cm path length were used.
An amount equivalent to 25.0 mg of ketoconazole
standard was accurately weighed and transferred to a
100 mL volumetric flask. After solubilization in methanol
with sonication, the volume was completed with same
solvent to obtain a solution containing 250.0 µg of
ketoconazole/mL. Six aliquots of this solution from 0.5 to
3.0 mL were transferred to 25 mL volumetric flasks. The
volume was completed with methanol and the final
concentrations of the solutions were 5.0, 10.0, 15.0, 20.0,
25.0 and 30.0 µg/mL of ketoconazole in respective
volumetric flasks. Absorptions of these solutions were
determined at 257 nm, using methanol as blank.
For specificity determination of the method, an
amount equivalent to 10.0 mg of standard ketoconazole
was accurately weighed and transferred to a 100 mL
volumetric flask and the volume was completed with
methanol. An aliquot of 5.0 mL was transferred to a
25 mL volumetric flask and volume completed with the
same solvent to obtain a solution containing 20.0 µg of
ketoconazole/mL. An amount of emulsion (500 mg)
equivalent to 10 mg of ketoconazole (sample 2) and
500 mg of placebo emulsion (emulsion without
ketoconazole) were separately weighed and transferred
to three 100 mL volumetric flasks. After adding 80 mL of
methanol to each flask, the resulting solutions were
sonicated during 15 min, and the volumes completed
with same solvent. The solutions were filtered and
5.0 mL aliquots were transferred to 25 mL volumetric
flasks and the volumes completed with methanol. These
solutions were analyzed by proposed Method I using
methanol as blank.
The precision of the method was determined by
analyzing three separate standard solutions and ten
aliquots of ketoconazole emulsion samples (sample 1 and
2), containing 20.0 µg/mL of ketoconazole each.
To perform the recovery tests an amount of 25.0 mg
of ketoconazole standard was weighed and transferred to
a 100 mL volumetric flask. The volume was completed
with methanol. An amount of 1.25 g of sample 2,
equivalent to 25.0 mg of ketoconazole was weighed and
transferred to a 100 mL volumetric flask. The drug was
solubilized in methanol by sonication for 15 min and vo-
lume was completed with the same solvent. The final
concentrations of both solutions were 250.0 µg of
ketoconazole/mL.
Appropriate volumes of standard solutions were
used to spike sample solutions at three concentration
levels. The spiked sample solutions were analyzed using
the proposed method.
High Performance Liquid Chromatography (Method II)
The mobile phase was constituted of a mixture of
triethylamine in methanol (1:500 v/v) and ammonium
acetate solution in water (1:200w/v), 75:25 v/v. The
analytical column was LiChrospher® 100 RP-18 (5µm)
(125x4 mm) in a LiChroCART® (Merck® Darmstadt,
Germany). All analyses were done under isocratic
conditions, at a flow rate of 1.0 mL/min and at ambient
temperature (24 ± 2 °C), with UV detection at 225 nm.
An amount of 10.0 mg of ketoconazole standard
was accurately weighed and transferred to a 100 mL
volumetric flask. After solubilization in methanol with
sonication, the volume was completed with same
TABLE I - Description of simulated pharmaceutical emulsion sample and commercial emulsion sample selected for
analyses
Components Simulated sample (Sample 1) Commercial  sample (Sample 2)*
Aqueous phase (A) %w/w
Propyleneglycol 5.00
Disodium edetate 0.20
Purified water q.s.p 100.00
Oil phase (B) % w/w Containing 20.0 mg of
Polawax® 15.00 ketoconazole per
Mineral oil 5.00 gram of emulsion
Butylhydroxytoluene 0.05
Phase (C) % w/w
Chemynol® 0.50
Ketoconazole 2.00
* Excipients not disclosed by firm.
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solvent to obtain a solution containing 100.0 µg of
ketoconazole/mL. An amount of 25.0 mg of terconazole
(internal standard) was weighed and transferred to a
100 mL volumetric flask. After the solubilization, in
methanol with sonication, the volume was completed
with same solvent. The final concentration was
250.0 µg of terconazole/mL.
Seven aliquots of ketoconazole standard solution from
2.0 to 8.0 mL were transferred to 10 mL volumetric flasks and
a 2.0 mL aliquot of internal standard was also added to each
flask. The volume was completed with mobile phase and the
final concentrations of the solutions were 20.0, 30.0, 40.0,
50.0, 60.0, 70.0 and 80.0 µg of ketoconazole/mL, along with
50.0 µg of terconazole/mL. These solutions were analyzed in
duplicate and the analytical curve was constructed by plotting
concentration of ketoconazole versus corresponding area
ratios of ketoconazole and internal standard.
The specificity of the method was analyzed using
standard ketoconazole, sample 2 and placebo solutions.
An amount of 10.0 mg of standard ketoconazole
was transferred to a 100 mL volumetric flask and volu-
me completed with methanol. An aliquot of 4.0 mL was
transferred to a 10 mL volumetric flask, 2.0 mL of
internal standard solution (250.0 µg of terconazole/mL)
was also added and the volume completed with
methanol. The final concentrations were 40.0 µg of
ketoconazole and 50.0 µg of terconazole/mL of solution.
An amount of sample 2  (1.0 g), equivalent to 20.0 mg of
ketoconazole was accurately weighed and transferred to
a 100 mL volumetric flask, 80 mL of methanol was
added and the solution sonicated for 15 min. The volume
was completed with methanol and resultant solution
filtered through Whatman filter paper no.1. An aliquot of
2.0 mL of filtrate was transferred to a 10 mL volumetric
flask. An aliquot of 2.0 mL of internal standard
(250.0 µg/mL) was also added to same flask and the vo-
lume was completed with the mobile phase. The final
concentrations were 40.0 µg of ketoconazole and
50.0 µg of terconazole/mL of solution. An amount of
1.0 g of placebo was weighed and submitted to same
treatment without addition of the internal standard.
In order to calculate the precision of the method
three solutions of standard ketoconazole were prepared as
described above. The final concentration of resultant
solution was 40.0 µg of ketoconazole and 50.0 µg of
terconazole/mL. Ten solutions of ketoconazole emulsion
(sample 1 and 2) were prepared containing 40.0 µg of
ketoconazole and 50.0 µg of terconazole/mL.
To perform the recovery tests 25.0 mg of ketoconazole
standard were weighed and transferred to a 100 mL
volumetric flask. After solubilization, the volume was
completed with methanol to obtain a solution containing
250.0 µg of ketoconazole/mL. An amount of 1.0 g of sample
2 was weighed and transferred to a 100 mL volumetric flask.
After the addition of 80 mL of methanol the solution was
sonicated during 15 min. The volume was completed with
methanol and the solution filtered. The final concentration
was 250.0 µg of ketoconazole/mL.
Appropriate volumes of standard and sample
solutions were transferred to 25 mL volumetric flasks and
analyzed using the proposed method. In all cases, an
aliquot of 5.0 mL of terconazole solution containing
250.0 µg/mL was also added.
RESULTS AND DISCUSSION
First-derivative UV Spectrophotometry (Method I)
The first-derivative UV spectrum of ketoconazole,
in a range from 211 nm to 295 nm, presented a maximum
absorption peak at 257 nm, without any interference from
excipients. The method was validated at 257 nm. The
analytical curve was constructed in a concentration range
from 5.0 to 30.0 µg of ketoconazole/mL. The linearity of
the curve was evaluated by linear regression analyses of
responses. The standard curve showed linearity within the
concentration range studied with a correlation coefficient
of 0.9997 (y=2.1x10-4 x + 1.5x10-3). The precision of the
method was reported as relative standard deviation (RSD)
(Table III). The accuracy of the proposed method was
confirmed by the obtained results (Table IV). Near 100%
recovery of ketoconazole from the matrix proves the
accuracy of the proposed method. Different excipients
used in the formulations (Table I) did not interfere in the
analyses using the proposed first-derivative UV
spectrophotometric method (Figure 2).
TABLE II - Analytical curve data of ketoconazole in pharmaceutical emulsions
Statistical parameters Method I Method II
Concentration range (µg/mL) 5.0-30.0 20.0-80.0
Regression equation y=2.1x10-4 x + 1.5x10-3 y = 6.1x10-2 x + 2.3x10-2
Correlation coefficient (r) 0.9997 0.9981
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High Performance Liquid Chromatography (Method II)
In the preliminary studies several mobile phases
were tested. The optimum and efficient separations
were obtained when diisopropylamine was substituted
by triethylamine (United States Pharmacopeia, 2005).
The chromatograms of standard ketoconazole and
terconazole can be observed in Figure 3B and those of
sample can be observed in Figure 3C. A base line
separation of ketoconazole and terconazole peaks was
obtained within approximately 6.0 min. The shorter
elution time makes the method especially useful for
routine analysis of ketoconazole in pharmaceutical
formulations. Analytical curve was constructed in a
TABLE III - Statistical data and results obtained in the determination of ketoconazole contained in pharmaceutical
emulsions
Statistical data Method I Method II
Sample 1 2 1 2
RSD (%) 0.56 0.41 2.13 1.25
Amount declared (mg/g) 20.00 20.00 20.00 20.00
Amount found (mg/g) 20.30 20.55 21.76 19.65
Confidence limit (p=95%) 101.49 ± 0.40 102.76 ± 0.30 108.79 ± 1.66 98.23 ± 0.87
TABLE IV - Results obtained in the recovery of ketoconazole standard solution added to sample 2 and analyzed by the
proposed methods
Method I Method II
Sample Concentration Recovery Concentration Recovery
(mg/mL) (%) (mg/mL) (%)
Added Found Added Found
10.0 10.3 103.4 10.0 10.0 100.0
2 15.0 15.0 100.0 20.0 20.0 100.0
20.0 19.4 97.0 30.0 30.4 101.3
FIGURE 2 – First-derivative ultraviolet absorption spectra in methanol: (A) placebo, (B) placebo with 20.0 µg/mL
ketoconazole standard, (C) ketoconazole standard, 20.0 µg/mL and (D) ketoconazole sample, 20.0 µg/mL.
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concentration range from 20.0 to 80.0 µg/mL. The
linearity of the curve was evaluated by linear regression
analysis of responses. The standard curve showed
linearity within the concentration range studied with
correlation coefficient of 0.9981 (y = 6.1x10-2 x+ 2.3x10-2).
The precision of the method reported as RSD can be
observed in Table III. The accuracy of the HPLC
method was confirmed by the results showed in the
Table IV.
The excipients of the emulsion samples did not in-
terfere in either ketoconazole quantitation or in the internal
standard peak (Figures 3A and 3C).
The validation data and sample analyses substantiate
the precision, accuracy, specificity and efficiency of the two
proposed methods in the determination of ketoconazole in
pharmaceutical emulsions.
CONCLUSIONS
Analytical curves were linear within a concentration
range from 5.0 to 30.0 μg/mL for Method I and 20.0 to
80.0 μ g/mL for Method II, with correlation coefficients of
0.9997 and 0.9981, respectively.
The proposed f irs t-derivat ive ul traviolet
spectrophotometric (Method I) and reversed phase high
performance liquid chromatographic methods (Method
II) presented good precision as is evident from intra-
day repeatability data. The relative standard deviation
(RSD) was 0.56% and 0.41% for simulated and
commercial emulsion formulations, respectively, using
Method I. The corresponding values were 2.13% and
1.25%, respectively, using Method II. The emulsion
samples containing ketoconazole can be analyzed with
more precision using proposed Method I, though RSD
values are acceptable in both cases.
The percentage recovery was 100.1% for the
Method I and 100.4% for the Method II and methods
could be considered accurate.
The specificity data show that the emulsion
excipients do not interfere in the analyses. In this case, the
first-derivative zero-crossing spectrophotometric method
presents a unique advantage that it permits determination
of ketoconazole in pharmaceutical emulsions even in the
presence of potential interfering excipients.
Based on these observations it was concluded that
the proposed methods can be applied for rapid
ketoconazole determination in pharmaceutical emulsions
with precision and accuracy.
RESUMO
Determinação do cetoconazol em emulsões por
espectrofotometria no ultravioleta por derivada de
primeira ordem e cromatografia líquida de alta
eficiência
Foram desenvolvidos e padronizados métodos por
espectrofotometria no ultravioleta (UV) por derivada
de primeira ordem (Método I) e cromatografia líquida
de alta eficiência (CLAE) (Método II) para a determi-
nação quantitativa de cetoconazol em formulações far-
macêuticas sob a forma de emulsão obtida no comércio
e formulada em laboratório. A espectrofotometria no
UV por derivada de primeira ordem foi padronizada
usando-se o método do zero pico a 257 nm, utilizando
metanol como solvente. A cromatografia líquida foi
realizada empregando-se uma coluna LiChrospher®
100 RP-18 (5 µm). A fase móvel utilizada foi a mistura
de trietilamina em metanol (1:500) e solução de
acetato de amônio em água (1:200) na proporção de
75:25 v/v, com vazão de 1 mL/min e detecção no UV de
225 nm. O tempo de retenção do cetoconazol foi de
3,9 min e do terconazol de 5,9 min, este último utiliza-
do com padrão interno. As curvas analíticas mostra-
ram linearidade dentro das concentrações de 5,0 a
30,0 mg/mL para o Método I e 20,0 a 80,0 mg/mL para
o Método II, com coeficientes de correlação linear de
0,9997 e 0,9981, respectivamente.O desvio padrão re-
lativo (DPR) foi de 0,56% e 0,41% para a amostra si-
mulada e comercial, respectivamente, empregando-se
o Método I. Para o Método II, os valores foram de
FIGURE 3 – Chromatograms of: (A) placebo; (B)
ketoconazole standard, 20.0 µg/mL (1) and terconazole
internal standard, 50.0 µg/mL (2); (C) sample (sample 2)
containing 20.0 µg/mL ketoconazole (1) and terconazole
internal standard, 50.0 µg/mL (2). Chromatographic
conditions: mobile phase: triethylamine in methanol (1:500)
and ammonium acetate solution in water (1:200), 75:25 (v/v),
flow rate 1.0 mL/min and UV detection at 225 nm;
LiChrospher® 100 RP-18 (5 µm) (125x4 mm) column in a
LiChroCART®, room temperature (24 ± 2 °C).
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2,13% e 1,25%, respectivamente. A porcentagem de re-
cuperação foi de 100,1% para o Método I e 100,4%
para o Método II. Os excipientes não interferiram nas
análises. Os resultados mostraram que os dois métodos
podem ser usados para a determinação rápida de
cetoconazol em formulações de emulsões com precisão,
exatidão e especificidade.
UNITERMOS: Cetoconazol. Emulsão. Espectrofotometria
no ultravioleta por derivada de primeira ordem.
Cromatografia líquida de alta eficiência.
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